证券代码:600789 股票简称:鲁抗医药 公告编号:临 2023-034 山东鲁抗医药股份有限公司 关于两全资子公司吸收合并完成工商登记变更的公告 法定代表人：曹海峰 注册资本：25588 万元 住 所：山东省济宁市邹城市邹城工业园区华鲁路 50 号 经营范围：许可项目：兽药生产；兽药经营；食品添加剂生产；饲料添加剂 生产【分支机构经营】；饲料生产【分支机构经营】。（依法须经批准的项目， 经相关部门批准后方可开展经营活动，具体经营项目以相关部门批准文件或许可 证件为准） 一般项目：技术进出口；货物进出口；饲料添加剂销售；食品添加剂销售； 技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；专用化学产 品销售（不含危险化学品）；化工产品销售（不含许可类化工产品）；生物化工 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东鲁抗医药股份有限公司（以下简称"公司"）于 2022 年 12 月 28 日召 开了十届董事会第十六次（临时）会议，审议通过了《关于全资子公司吸收合并 的议案》，同意全资子公司山东鲁抗舍里乐药 ...

证券代码：600789 证券简称：鲁抗医药 公告编号：2023-021 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度及 2023 年第 一季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息 披露允许的范围内就投资者普遍关注的问题进行回答。 山东鲁抗医药股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 05 月 11 日(星期四)至 05 月 17 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 lkpc_dmc@126.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 山东鲁抗医药股份有限公司（以下简称"公司"）已于 2023 年 4 月 19 日发 布公司 2022 年度报告和 2023 年第 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 1,669,812,908.04, representing a year-on-year increase of 25.42% compared to CNY 1,324,581,073.87 in the same period last year[3]. - The net profit attributable to shareholders of the listed company was CNY 45,688,589.04, a slight increase of 1.59% from CNY 44,588,853.42 in the previous year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses surged by 77.02% to CNY 41,375,154.29 from CNY 23,629,646.82 in the same period last year[3]. - The company reported a basic earnings per share of CNY 0.05, unchanged from the previous year[4]. - The total comprehensive income for the first quarter of 2023 was CNY 47,414,780.36, an increase from CNY 46,090,528.29 in the same period of 2022, representing a growth of approximately 2.86%[16]. Cash Flow - The net cash flow from operating activities increased by 92.05% to CNY 130,889,329.27, compared to CNY 68,459,009.16 in the previous year[4]. - The net cash flow from operating activities for Q1 2023 was CNY 130,889,329.27, significantly higher than CNY 68,153,420.75 in Q1 2022, indicating an increase of about 92.4%[18]. - The total cash inflow from financing activities was CNY 697,270,082.10 in Q1 2023, compared to CNY 228,329,538.31 in Q1 2022, reflecting a substantial increase of approximately 205.5%[19]. - The net cash flow from financing activities for Q1 2023 was -CNY 137,996,819.86, worsening from -CNY 9,018,694.18 in Q1 2022[19]. - The cash and cash equivalents at the end of Q1 2023 stood at CNY 323,314,673.48, down from CNY 395,130,807.40 at the end of Q1 2022, a decrease of about 18.2%[19]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 8,548,945,159.23, a decrease of 2.50% from CNY 8,727,665,447.53 at the end of the previous year[4]. - Current liabilities decreased to ¥3,526,689,113.33 from ¥4,129,057,002.94, representing a reduction of 14.6%[12]. - The total liabilities decreased to ¥4,979,764,208.53 from ¥5,220,496,898.35, a decline of 4.6%[13]. - Long-term borrowings increased to ¥1,236,885,323.06 from ¥867,176,000.00, indicating a rise of 42.5%[12]. Shareholder Information - The company has 116,523 common shareholders as of the end of the reporting period[8]. - The top shareholder, Hualu Holdings Group Co., Ltd., holds 20.91% of the shares, totaling 185,896,620 shares[8]. Research and Development - Research and development expenses increased to ¥72,066,772.99 in Q1 2023, compared to ¥60,176,722.79 in Q1 2022, marking a rise of 19.7%[15]. Inventory and Expenses - Inventory as of March 31, 2023, was ¥1,503,632,882.92, slightly up from ¥1,480,685,151.67 at the end of 2022[12]. - The cash paid for purchasing goods and services in Q1 2023 was CNY 635,306,475.83, down from CNY 741,247,430.29 in Q1 2022, representing a decrease of about 14.3%[18]. - The company received CNY 18,184,609.68 in tax refunds during Q1 2023, compared to CNY 23,881,168.78 in Q1 2022, a decline of approximately 23.9%[18]. - The company incurred cash outflows of CNY 73,776,345.22 for taxes in Q1 2023, which is significantly higher than CNY 27,151,145.58 in Q1 2022, an increase of about 171.5%[18]. Acquisition - The company acquired a 60% stake in Shandong Rukang Zhonghe Environmental Technology Co., Ltd. for CNY 62.0659 million, which was completed on August 24, 2022, and is now a wholly-owned subsidiary[4].

Financial Performance - In 2022, the company achieved a consolidated net profit attributable to shareholders of the parent company of CNY 138,013,129.39, representing a 54.90% increase compared to the previous year[6]. - The operating revenue for 2022 was CNY 5,621,441,903.66, which is a 14.17% increase from CNY 4,923,783,870.87 in 2021[22]. - The net cash flow from operating activities reached CNY 444,377,008.97, marking a significant increase of 150.36% compared to CNY 177,492,024.62 in the previous year[22]. - The total assets of the company at the end of 2022 were CNY 8,727,665,447.53, an increase of 11.57% from CNY 7,822,429,397.11 at the end of 2021[23]. - The net assets attributable to shareholders of the parent company were CNY 3,356,856,234.48, reflecting a 2.25% increase from CNY 3,282,963,859.81 in 2021[23]. - Basic earnings per share increased by 60% to CNY 0.16 in 2022 from CNY 0.10 in 2021[24]. - The company reported a net profit excluding non-recurring gains and losses of CNY 86,962,978.51, which is a 141.76% increase from CNY 35,971,269.00 in the previous year[22]. - The gross profit from the main business reached 1.22 billion RMB, an increase of 5.68% compared to the previous year[50]. - The total revenue for 2022 was approximately CNY 5.54 billion, with a gross profit margin of 22.01%, reflecting a year-over-year decrease of 1.67 percentage points[59]. Strategic Developments - The company plans to distribute a cash dividend of CNY 0.55 per 10 shares (including tax) to all shareholders[6]. - The company’s future plans and strategic developments are subject to investment risks and do not constitute a commitment to investors[7]. - The company plans to continue expanding its product pipeline and enhancing marketing capabilities to drive future growth[59]. - The company aims to maintain and improve market share in niche products through flexible sales strategies and optimized business lines[86]. - The company will actively conduct industry policy research to align with policy directions and enhance brand building[86]. - The company is committed to promoting transformation and upgrading through consistent evaluation and new product development[87]. - The company plans to enhance research and development efforts, focusing on anti-infection products and expanding its product pipeline across multiple therapeutic areas[87]. Research and Development - R&D investment for 2022 was CNY 311 million, with significant progress in the pipeline for anti-infection and cardiovascular drugs[35]. - The company holds 47 new patent authorizations in 2022, enhancing its technological and innovation capabilities[51]. - The company has developed a complete product chain from fermentation raw materials to semi-synthetic raw materials and formulations, covering over 500 specifications[44]. - The company is focusing on innovative drugs and generic drug applications, biotechnology product development, and product transformation to enhance its product portfolio[106]. - The total R&D investment for the reporting period was CNY 311 million, accounting for 5.52% of total operating revenue, which is relatively high compared to industry peers[106]. - The company is actively expanding its product types and strengthening its product chain through scientific research and development efforts[106]. Market Performance - Revenue from formulation products reached CNY 1.902 billion in 2022, with new product sales contributing over CNY 70 million[33]. - The revenue from the antibiotic segment was CNY 255.82 million, with a gross profit margin of 18.53%, showing a year-over-year decrease of 10.46%[59]. - The revenue from veterinary antibiotics increased significantly, reaching CNY 2.31 billion, with a gross profit margin of 15.66%, marking a year-over-year increase of 43.04%[59]. - The domestic revenue accounted for CNY 4.78 billion, with a gross profit margin of 23.96%, reflecting a year-over-year increase of 16.09%[59]. - The company is recognized as one of the four major antibiotic production bases in China, with a strong market presence in penicillin and cephalosporin products[52]. Operational Efficiency - The company achieved a cost reduction of CNY 78.7827 million through efficiency improvements and production optimization[34]. - The company invested CNY 157 million in production automation, establishing 12 post-packaging production lines and deploying 14 robots, resulting in a 45.77% increase in labor productivity[37]. - The company’s automation and information technology initiatives have been recognized as a national pilot demonstration project by the Ministry of Industry and Information Technology[36]. - The company has implemented a dynamic management system for suppliers, ensuring quality and reducing procurement costs[45]. Environmental Responsibility - The company’s environmental investment in 2022 was CNY 173.39 million, with successful completion of pollution control assessments for three subsidiaries[38]. - The company is committed to enhancing its environmental and safety standards in response to increasing regulatory pressures, aiming for compliance with national carbon neutrality goals[135]. - The company has established a governance structure to protect the interests of shareholders, particularly minority shareholders, ensuring transparent information disclosure[191]. - The company was recognized as a national-level "Green Factory," reflecting its commitment to environmental responsibility and sustainable practices[188]. Governance and Compliance - The company held two shareholder meetings during the reporting period, ensuring compliance with legal requirements and facilitating shareholder participation[138]. - The board of directors operates under strict regulations, with established committees to enhance decision-making and oversight functions[139]. - The company adheres to strict information disclosure regulations, preventing selective disclosure and insider trading[141]. - The company has a comprehensive risk management report that was approved in the last board meeting of the year[156]. Future Outlook - The company aims for a revenue target of 6 billion yuan in 2023, representing a year-on-year growth of over 7%[124]. - Financial guidance for the upcoming fiscal year suggests a projected revenue growth of approximately 15%[148]. - The company plans to enhance the profitability and competitiveness of its raw materials through the "Peak Plan" and aims to optimize technology and quality while reducing costs[125]. - The company is positioned to benefit from the stable implementation of volume-based procurement policies, seeking innovation and channel expansion to enhance profitability[121].

Group 1: Event Details - The event is organized by Shandong Securities Regulatory Bureau and Shandong Listed Companies Association [1] - The online event will take place on November 16, 2022, from 14:00 to 16:00 [1] - Investors can participate via the "Investor Relations Interactive Platform" provided by P5W [1] Group 2: Company Representatives - The company's Chairman, Mr. Peng Xin, will be present for the online communication [1] - The Chief Financial Officer, Mr. Li Li, will also participate in the event [1] - Other representatives include Board Secretary Mr. Tian Lixin and Securities Affairs Representative Mr. Bao Qiangming [1] Group 3: Discussion Topics - Topics for discussion include corporate governance and social responsibility/ESG [1] - The company's operational status and development strategy will be addressed [1] - Risk prevention and investor protection, along with the third-quarter report, will be key points of interest [1]

Financial Performance - Operating revenue for the period was ¥1,301,217,382.71, representing a year-on-year growth of 35.54%[11] - Net profit attributable to shareholders was ¥47,955,112.28, a significant increase of 693.98% compared to the same period last year[12] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥43,492,912.12, up from a loss of ¥4,553,556.66 in the previous year[11] - Operating profit surged to ¥59,642,621.50, a remarkable increase of 332.17% driven by higher gross profit[18] - Net profit for Q1 2021 was ¥60,368,645.93, a substantial rise from ¥10,367,468.76 in Q1 2020, showcasing improved profitability[36] Assets and Liabilities - Total assets at the end of the reporting period reached ¥7,544,777,894.62, an increase of 3.72% compared to the end of the previous year[11] - Total liabilities rose to ¥4,132,484,728.42, compared to ¥3,913,554,693.04[26] - Shareholders' equity increased to ¥3,412,293,166.20, up from ¥3,359,270,143.02[26] - Total assets increased to ¥7,544,777,894.62, up from ¥7,272,824,836.06[24] - Total operating costs for Q1 2021 were ¥1,242,225,586.28, up from ¥954,981,063.65 in Q1 2020, reflecting a significant increase in operational expenses[36] Cash Flow - Cash flow from operating activities showed a net outflow of ¥21,023,245.89, an improvement from a net outflow of ¥79,185,003.48 in the previous year[11] - Cash inflow from operating activities totaled 582,593,742.02 RMB, up from 439,399,934.75 RMB year-over-year, reflecting a 32.5% increase[50] - The net cash flow from operating activities was -69,108,494.01 RMB, an improvement from -86,456,336.00 RMB in the previous year, indicating a reduction in cash outflow[50] - Cash outflow for operating activities was 651,702,236.03 RMB, compared to 525,856,270.75 RMB in the prior year, representing a 23.9% increase[50] Expenses - Sales expenses reached ¥162,764,591.00, a 51.06% increase driven by higher marketing costs[18] - R&D expenses amounted to ¥55,239,151.06, up 55.07% due to increased investment in research[18] - R&D expenses increased to ¥55,239,151.06 in Q1 2021, compared to ¥35,621,421.06 in Q1 2020, indicating a focus on innovation[36] Shareholder Information - The total number of shareholders at the end of the reporting period was 151,747[14] Other Financial Metrics - The weighted average return on net assets increased by 1.22 percentage points to 1.42%[11] - Basic and diluted earnings per share for Q1 2021 were both ¥0.05, compared to ¥0.01 in Q1 2020[43] - The total comprehensive income for Q1 2021 was approximately ¥48.60 million, significantly higher than ¥7.49 million in Q1 2020[39] - The tax expenses for Q1 2021 were approximately ¥10.77 million, compared to ¥2.88 million in Q1 2020, indicating an increase in tax burden[39]

Financial Performance - Operating income for the first nine months was CNY 3,065,608,964.86, representing a year-on-year increase of 12.23%[17] - Net profit attributable to shareholders of the listed company reached CNY 230,209,742.13, up 126.49% year-on-year[17] - Basic earnings per share increased by 116.67% to CNY 0.26[17] - The weighted average return on net assets rose by 3.92 percentage points to 7.34%[17] - The company reported a total profit of ¥10,575,625.32 for Q3 2020, down from ¥25,492,601.20 in Q3 2019, a decline of 58.5%[52] - The net profit for Q3 2020 was -¥50,095,389.26, compared to -¥8,773,041.88 in Q3 2019, indicating a significant decline in profitability[64] - The total comprehensive income attributable to the parent company for Q3 2020 was ¥1,797,855.01, compared to ¥19,936,092.69 in Q3 2019, showing a decrease of about 90.0%[61] Assets and Liabilities - Total assets at the end of the reporting period were CNY 7,010,934,318.92, a decrease of 1.10% compared to the end of the previous year[17] - Total liabilities decreased to ¥3,638,997,692.06 from ¥3,917,627,675.83, a decrease of approximately 7.1%[39] - Current liabilities decreased to ¥2,899,727,904.26 from ¥3,201,220,573.52, a reduction of about 9.4%[37] - The company’s total assets reached ¥5,846,787,231.79, up from ¥5,758,273,851.13 year-over-year[44] - Total liabilities were approximately $3.01 billion, with non-current liabilities accounting for about $520 million[86] - The company reported a long-term equity investment of approximately $55.84 million, indicating strategic investments in other entities[78] Cash Flow - Net cash flow from operating activities for the first nine months was CNY 80,989,879.15, an increase of 105.55% compared to the same period last year[17] - The cash flow from operating activities for the first three quarters of 2020 was ¥2,455,563,873.80, down from ¥3,220,785,625.12 in the same period of 2019, a decline of approximately 23.7%[66] - Cash inflow from financing activities reached 2,045,502,640.00, significantly higher than 1,155,252,241.63 in the previous period, showing strong borrowing activity[69] - The net cash flow from financing activities was 190,570,600.02, an increase from 132,739,726.13, suggesting effective capital management[71] - The company experienced a net increase in cash and cash equivalents of -27,576,604.94, compared to -7,001,381.25 in the previous period, highlighting cash flow challenges[71] Shareholder Information - Net assets attributable to shareholders of the listed company increased by 6.48% to CNY 3,216,861,067.05[17] - The total number of shareholders at the end of the reporting period was 161,966[21] - The largest shareholder, Hualu Holdings Group Co., Ltd., held 21.12% of the shares[21] Investments and Expenditures - Research and development expenses in Q3 2020 amounted to ¥49,289,820.96, compared to ¥35,242,474.95 in Q3 2019, indicating a 39.9% increase[49] - The company is focusing on enhancing its R&D capabilities to drive future growth, as indicated by the increased R&D spending[61] - The company has ongoing construction projects valued at approximately $660.34 million, reflecting investment in future growth[78] Accounting Policies - The implementation of the new revenue recognition standard did not have a significant impact on the financial statements, with adjustments made only for contracts not completed by January 1, 2020[90] - Under the new leasing standard, the company recognized right-of-use assets and lease liabilities, with long-term payables adjusted to approximately $460.64 million[92] - The company has adopted new accounting policies effective January 1, 2020, for both revenue recognition and leasing, ensuring compliance with updated standards[90]

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 1,998,974,955.67, representing a 7.87% increase compared to CNY 1,853,115,369.55 in the same period last year[22]. - Net profit attributable to shareholders of the listed company reached CNY 228,411,887.12, a significant increase of 179.55% from CNY 81,708,391.92 in the previous year[22]. - Basic earnings per share for the reporting period was CNY 0.2595, up 179.63% from CNY 0.0928 in the same period last year[24]. - The company's total assets as of the end of the reporting period were CNY 7,157,521,643.48, a slight increase of 0.96% from CNY 7,089,268,238.84 at the end of the previous year[24]. - The weighted average return on net assets increased to 7.29%, up by 4.54 percentage points from 2.75% in the previous year[24]. - The net profit after deducting non-recurring gains and losses was CNY 3,157,388.37, down 95.36% from CNY 67,987,696.47 in the previous year[22]. - The company's net assets attributable to shareholders reached CNY 3,251,855,640.90, an increase of 7.64% from CNY 3,021,159,128.79 at the end of the previous year[24]. - The diluted earnings per share was CNY 0.2571, reflecting a 177.05% increase from CNY 0.0928 in the same period last year[24]. - The company achieved a net profit attributable to shareholders of 228 million yuan, an increase of 147 million yuan, representing a growth of 179.55% year-on-year[41]. - The company reported a total revenue of 1.999 billion yuan for the first half of 2020, a year-on-year increase of 7.87%[50]. Cash Flow and Investments - The net cash flow from operating activities was CNY 3,631,147.69, a decrease of 96.02% compared to CNY 91,140,543.68 in the same period last year[22]. - The company reported a significant increase in asset disposal income of CNY 208 million, attributed to land compensation agreements[70]. - The total amount of long-term borrowings increased by 358.88% to approximately CNY 448.31 million, reflecting a strategy to leverage debt for growth[73]. - The company secured a low-interest loan of 200 million yuan from the government to supplement working capital and reduce costs[51]. - The company reported a net cash outflow from operating activities of ¥55,068,469.55, contrasting with a net inflow of ¥6,583,597.41 in the same period last year[169]. - The total cash flow from investment activities was negative at -¥62,449,557.87, compared to -¥45,392,206.31 in the previous year, indicating a worsening investment cash flow situation[169]. Research and Development - The company has 17 generic drug projects under research and development, with 5 varieties of active pharmaceutical ingredients undergoing process changes[55]. - The company has integrated R&D resources to form a dedicated research institute, enhancing its new product development capabilities[35]. - Research and development expenses rose by 24.53% to approximately CNY 82.08 million, indicating a focus on innovation[64]. - The company obtained 14 patent authorizations, including 3 invention patents, during the reporting period[55]. - Research and development expenses for the first half of 2020 were ¥82,078,005.73, compared to ¥65,911,671.45 in the same period last year, an increase of 24.5%[152]. Market and Industry Position - The pharmaceutical manufacturing industry saw a cumulative value-added growth of 1.8% in the first half of 2020, with total revenue of ¥12,390.4 billion, remaining flat year-on-year[36]. - The company is recognized as a national high-tech enterprise and has a leading market share in core products such as penicillin and semi-synthetic antibiotics[39]. - The company is actively participating in provincial drug centralized procurement, adapting to new pricing and bidding strategies[34]. - The company’s sales model includes channel distribution, terminal delivery, and academic promotion, ensuring extensive market coverage[33]. - The company plans to continue focusing on market expansion and new product development to drive future growth[161]. Environmental Management - The company has established a comprehensive environmental management system and passed ISO14001 certification, enhancing its core competitive advantage in environmental protection[48]. - The company has implemented strict environmental protection measures, adhering to laws such as the Environmental Protection Law and the Water Pollution Prevention Law, with a focus on monitoring and managing pollutants[108]. - The company has established a wastewater treatment facility with a capacity of 80 tons per day, ensuring compliance with discharge standards[109]. - The company has introduced advanced technologies for VOCs treatment, significantly improving the effectiveness of pollution control measures[108]. - All subsidiaries have achieved compliance in pollutant discharge, with no environmental pollution incidents reported in the first half of 2020[118]. Risks and Challenges - The company faces risks related to industry policy changes, which may lead to significant fluctuations in net profit compared to the previous year due to intensified regulatory measures in the pharmaceutical industry[78]. - Environmental and safety production risks are heightened due to stricter regulations and potential equipment failures, despite the company's ongoing commitment to environmental protection[81]. - The company acknowledges R&D risks, including high investment and low success rates, which may lead to mismatches between R&D input and revenue[82]. - The macroeconomic environment, particularly the impact of the COVID-19 pandemic, poses risks to the pharmaceutical industry, affecting operational conditions and growth[83]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 182,299[124]. - The largest shareholder, Hualu Holdings Group Co., Ltd., held 185,896,620 shares, representing 21.12% of the total shares[124]. - The new controlling shareholder is Hualu Holdings Group Co., Ltd., with the change effective from March 10, 2020[130]. - The company did not propose any profit distribution or capital reserve increase for the first half of 2020[88]. Financial Position - Total current assets increased to ¥2,724,486,428.52 as of June 30, 2020, up from ¥2,585,118,402.03 at the end of 2019, representing a growth of approximately 5.4%[136]. - Total liabilities decreased to ¥3,752,174,203.65 from ¥3,917,627,675.83, a reduction of about 4.2%[141]. - The company's total equity attributable to shareholders increased to ¥3,251,855,640.90 from ¥3,021,159,128.79, marking a growth of approximately 7.6%[141]. - The company’s long-term borrowings increased to ¥448,314,236.08 from ¥97,697,364.05, indicating a significant rise of approximately 358.5%[141].

Financial Performance - The company reported a net profit attributable to shareholders of 6.04 million RMB, a decrease of 87.50% compared to the previous year, which was a reduction of 42.26 million RMB [15]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -4.55 million RMB, a decrease of 111.33% year-on-year [15]. - The company's net profit for Q1 2020 was CNY 7,492,362.99, a significant decrease from CNY 50,732,617.70 in Q1 2019, representing a decline of approximately 85.2% [49]. - The net profit for Q1 2020 was ¥65,534,794.43, down from ¥72,888,930.29 in Q1 2019, indicating a decrease of 10.1% [44]. - The total profit for Q1 2020 was CNY 10,367,468.76, down from CNY 56,003,388.98 in Q1 2019, reflecting a decrease of approximately 81.5% [49]. - Basic and diluted earnings per share were both 0.01 RMB, down 85.71% from the previous year [12]. - The company's basic and diluted earnings per share for Q1 2020 were both CNY 0.01, down from CNY 0.07 in Q1 2019, a decrease of 85.7% [49]. Revenue and Costs - The operating revenue for the first quarter was 960.05 million RMB, representing a year-on-year increase of 2.45% [12]. - Total operating revenue for Q1 2020 was ¥960,049,128.01, an increase of 2.0% compared to ¥937,091,064.09 in Q1 2019 [44]. - Total operating costs for Q1 2020 were ¥954,981,063.65, up from ¥887,076,717.88 in Q1 2019, reflecting a significant increase of 7.6% [44]. - The company's operating costs for Q1 2020 were CNY 335,182,257.27, reduced from CNY 394,098,557.23 in Q1 2019, indicating a decrease of about 14.9% [49]. Cash Flow - The net cash flow from operating activities was -79.19 million RMB, a significant decline of 311.80% compared to the previous year [12]. - The net cash flow from operating activities was -79,185,003.48 RMB, a decrease from 37,385,987.66 RMB in the previous period, indicating a significant decline in operational performance [55]. - Cash inflow from operating activities was 1,086,955,111.43 RMB, slightly down from 1,139,129,941.74 RMB, suggesting a decline in revenue generation [55]. - Cash outflow for investing activities was 124,881,008.01 RMB, compared to 227,059,401.36 RMB previously, showing a reduction in investment expenditures [55]. - The total cash and cash equivalents at the end of the period amounted to 624,975,826.82 RMB, down from 676,886,638.18 RMB, indicating a decrease in liquidity [57]. Assets and Liabilities - Total assets at the end of the reporting period were 7.33 billion RMB, an increase of 3.39% from the end of the previous year [12]. - Total current assets amounted to ¥2,741,721,680.00, an increase from ¥2,585,118,402.03 [29]. - Total liabilities increased to ¥4,150,289,239.99 from ¥3,917,627,675.83 [35]. - Total equity reached ¥3,179,132,926.00, up from ¥3,171,640,563.01 [35]. - Current liabilities totaled ¥3,201,220,573.52, including short-term borrowings of ¥1,057,000,000.00 and accounts payable of ¥715,306,434.00 [65]. - Total liabilities reached ¥3,917,627,675.83, with non-current liabilities at ¥716,407,102.31, including long-term borrowings of ¥97,697,364.05 [65]. Shareholder Information - The company’s major shareholder, Hualu Holdings Group, holds 21.12% of the shares, making it the direct controlling shareholder [23]. - Shareholders' equity totaled ¥3,171,640,563.01, with total equity attributable to the parent company at ¥3,021,159,128.79 [67]. Operational Challenges - The company faced significant impacts on its product procurement, production, and sales due to the COVID-19 pandemic, leading to reduced gross profit [15]. - The market price of veterinary medicine products declined due to the ongoing African swine fever epidemic, adversely affecting profits [15]. Other Financial Metrics - Financial expenses decreased by 45.53% to ¥11,891,900.54 mainly due to an increase in exchange gains [25]. - Other income surged by 617.25% to ¥10,808,245.94 primarily from increased government subsidies received [25]. - Investment income dropped by 87.84% to ¥819,362.55 mainly due to the maturity of structured deposits [25]. - Research and development expenses for Q1 2020 amounted to ¥35,621,421.06, compared to ¥32,654,094.66 in Q1 2019, indicating a growth of 9.0% [44]. - The company reported a significant increase in operating expenses due to pandemic-related donations, rising by 1,686,342.81% to ¥3,659,243.61 [25].

2018 年第三季度报告 公司代码：600789 公司简称：鲁抗医药 山东鲁抗医药股份有限公司 2018 年第三季度报告 | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 9 | 2018 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人彭欣、主管会计工作负责人李利及会计机构负责人（会计主管人员）彭强保证季 度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 1 / 21 | 目录 | | --- | 2.1 主要财务数据 3 / 21 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度末增 减(%) 总资产 6,503,059,030.79 5,201,916,245.07 25.01 归属于上市公司 股东的净资产 2,9 ...